The estimated Net Worth of Gil M Labrucherie is at least $11.3 Millón dollars as of 15 May 2022. Mr. Labrucherie owns over 17,448 units of Nektar Therapeutics stock worth over $391,131 and over the last 17 years he sold NKTR stock worth over $3,408,846. In addition, he makes $7,488,840 as Chief Financial Officer, Chief Operating Officer y Senior Vice President at Nektar Therapeutics.
Sign up
Mr. Labrucherie NKTR stock SEC Form 4 insiders trading
Gilbert has made over 50 trades of the Nektar Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 17,448 units of NKTR stock worth $68,920 on 15 May 2022.
The largest trade he's ever made was exercising 200,000 units of Nektar Therapeutics stock on 2 March 2017 worth over $1,340,000. On average, Gilbert trades about 16,501 units every 34 days since 2007. As of 15 May 2022 he still owns at least 312,905 units of Nektar Therapeutics stock.
You can see the complete history of Mr. Labrucherie stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gilbert Labrucherie biography
Gilbert M. Labrucherie J.D. serves as Chief Financial Officer, Chief Operating Officer, Senior Vice President of the Company. Mr. Labrucherie has served as our Senior Vice President, Chief Financial Officer since June 2016, and added the role of Chief Operating Officer in October 2019. Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer. From October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open. While at E2open, Mr. Labrucherie was responsible or global corporate alliances and merger and acquisitions. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. Mr. Labrucherie received his J.D. from the Berkeley Law School and his B.A. from the University of California Davis.
What is the salary of Gilbert Labrucherie?
As the Chief Financial Officer, Chief Operating Officer y Senior Vice President of Nektar Therapeutics, the total compensation of Gilbert Labrucherie at Nektar Therapeutics is $7,488,840. There are 2 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
How old is Gilbert Labrucherie?
Gilbert Labrucherie is 48, he's been the Chief Financial Officer, Chief Operating Officer y Senior Vice President of Nektar Therapeutics since 2019. There are 14 older and 4 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
What's Gilbert Labrucherie's mailing address?
Gil's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Insiders trading at Nektar Therapeutics
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie y John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
What does Nektar Therapeutics do?
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
What does Nektar Therapeutics's logo look like?
Complete history of Mr. Labrucherie stock trades at Nektar Therapeutics
Nektar Therapeutics executives and stock owners
Nektar Therapeutics executives and other stock owners filed with the SEC include:
-
Jonathan Zalevsky,
Chief Research and Development Officer -
Howard Robin,
President, Chief Executive Officer, Director -
Gilbert Labrucherie,
Chief Financial Officer, Chief Operating Officer, Senior Vice President -
John Northcott,
Senior Vice President and Chief Commercial Officer -
Howard W. Robin,
CEO, Pres & Director -
Jillian Thomsen,
Senior Vice President - Finance, Chief Accounting Officer -
Gilbert M. Labrucherie J.D.,
Sr. VP, CFO & COO -
Dr. Jonathan Zalevsky,
Chief R&D Officer -
John P. Northcott,
Sr. VP & Chief Commercial Officer -
Mark A. Wilson,
Sr. VP, Gen. Counsel & Sec. -
Myriam Curet,
Independent Director -
Robert Chess,
Independent Chairman of the Board -
Roy Whitfield,
Lead Independent Director -
R. Scott Greer,
Independent Director -
Karin Eastham,
Independent Director -
Jeff Ajer,
Independent Director -
Dr. Brian L. Kotzin,
Sr. VP of Clinical Devel. & Head of Immunology -
Dr. Mary Tagliaferri L.Ac., M.D.,
Sr. VP & Exec. Clinical Fellow -
Jennifer Ruddock,
Sr. VP of Strategy & Corp. Affairs -
Robert Bacci,
Sr. VP of HR and Facilities -
Jillian B. Thomsen,
Sr. VP of Fin. & Chief Accounting Officer -
Lutz Lingnau,
Director -
Dennis L Winger,
Director -
Ivan P. Gergel,
SVP Drug Development & CMO -
Maninder Hora,
SVP Pharma Dev and Mfg -
Christopher A Kuebler,
Director -
Joseph J Krivulka,
Director -
Melvin Perelman,
Director -
Ajit Gill,
CEO & President -
Track Capital, Lp Deep Trac...,
-
Randall W Moreadith,
SVP Drug Development -
Bharat M Chowrira,
COO & Head of PEGylation BU -
Robert Medve,
Chief Medical Officer -
Nevan C Elam,
General Counsel and Secretary -
Timothy Harkness,
SVP & Chief Financial Officer -
John Stuart Patton,
Chief Scientific Officer -
Irwin Lerner,
Director -
Michael A/Ca Brown,
Director -
Masuoka K. Lorianne,
SVP & Chief Medical Officer -
Susan Wang,
Director -
Rinko Ghosh,
SVP & Chief Business Officer -
David Johnston,
SVP, Research & Development -
Ajay Bansal,
CFO, VP Finance & Admin -
Hoyoung Huh,
Chief Operating Officer -
J Milton Harris,
President of Nektar AL -
James B Glavin,
Director -
John Nicholson,
SVP & Chief Operating Officer -
Stephen K Doberstein,
SVP & Chief Scientific Officer -
Gil M Labrucherie,
SVP, COO & CFO -
Diana Brainard,
Director -
Mark Andrew Wilson,
Chief Legal Officer